Loading...
Market
Market reaction to Promega's STK33 trial results within 3 months
5
Resolution / Starting Odds
Significant increase in Promega's stock price • 33%
Moderate increase in Promega's stock price • 33%
No significant change in Promega's stock price • 34%
Stock market data and financial news reports
Story
Study Shows Promise for Nonhormonal Reversible Male Contraceptive Targeting STK33 in Mice
May 24, 2024, 10:14 AM
A new study has highlighted the potential of STK33, a protein essential for male fertility in humans and mice, as a target for nonhormonal and reversible male contraceptives. The study, sponsored by Promega and published in Science Magazine, demonstrated the effectiveness of CDD-2807, a tool compound that achieves reversible inhibition of spermatogenesis in mice. An injection that temporarily affects sperm movement has shown promise as a potential male contraceptive. The targeted inhibition of serine/threonine kinase 33 is central to this contraceptive method.
View original story
Similar markets
Significant stock price increase (>15%) • 25%
Moderate stock price increase (5-15%) • 25%
Little to no change (<5%) • 25%
Stock price decrease • 25%
Significant stock price increase (over 15%) • 25%
Moderate stock price increase (5-15%) • 25%
Little to no change (0-5%) • 25%
Stock price decrease • 25%
Significant increase in J&J stock price • 33%
Moderate increase in J&J stock price • 34%
No significant change in J&J stock price • 33%
Stock price rises significantly • 25%
Stock price remains stable • 25%
Stock price fluctuates moderately • 25%
Stock price falls significantly • 25%
Stock price increases 15% or more • 33%
Stock price remains stable (within 5% of current price) • 34%
Stock price decreases 15% or more • 33%
Increase more than 10% • 25%
Increase 5% to 10% • 25%
Decrease or change less than 5% • 25%
Decrease more than 5% • 25%
Significant increase in Alphabet's stock price • 33%
Little to no change in Alphabet's stock price • 33%
Decrease in Alphabet's stock price • 33%
Stock Price Increases • 33%
Stock Price Decreases • 33%
Stock Price Remains Stable • 34%
Significant growth (>15% increase) • 33%
Moderate growth (5-15% increase) • 34%
No significant change (<5% increase or decrease) • 33%
Increase in Robinhood's stock price • 33%
Decrease in Robinhood's stock price • 33%
No significant change in stock price • 34%
Significant increase (>20%) • 33%
Moderate increase (5-20%) • 33%
No significant change (<5%) • 34%
Significant increase • 25%
Significant decrease • 25%
Minimal impact • 25%
High volatility • 25%